When building your watch list, focus on stocks with an 80 or higher RS Rating. UroGen Pharma just cleared that benchmark with an upgrade from 75 to 81.
Looking For The Best Stocks To Buy And Watch? Start Here
IBD's proprietary rating tracks share price performance with a 1 (worst) to 99 (best) score. The rating shows how a stock's price movement over the trailing 52 weeks compares to all the other stocks in our database.
Over 100 years of market history shows that the best stocks often have an RS Rating north of 80 as they begin their biggest price moves.
While UroGen Pharma is not near a proper entry right now, see if it is able to form and break out of a proper consolidation.
The company showed 0% earnings growth in its most recent report. Sales rose 8%.
UroGen Pharma holds the No. 188 rank among its peers in the Medical-Biomed/Biotech industry group. Exelixis, TG Therapeutics and Inhibrx Biosciences are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Which Stocks Are Showing Improved Price Performance?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
